|
Active substance |
Nivolumab |
|
Holder |
Bristol-Myers Squibb NV |
|
Status |
Closed |
|
Indication |
Medical Need Program with Opdivo (nivolumab) for the treatment of anti-PD-1-treatment naïve patients with advanced renal clear-cell carcinoma who have progressed after or failed at least one prior treatment with an anti-angiogenic agent |
|
Public documents |
|
|
Last update |
06/01/2017 |
Opdivo
Last updated on 03/04/2024